Stay informed about the latest in drug development with BioPharma Dive’s free newsletter, delivered straight to your inbox. In the […]

Xoma Royalty Corp. has agreed to buy Mural Oncology, a biotech company focused on cancer treatments, for $2.035 per share.

The obesity drug market is currently dominated by two major players: Eli Lilly and Novo Nordisk. Both companies are working

Over the next five years, many top-selling cancer drugs from major pharmaceutical companies will lose their patent protection. This is

A report from the Make America Healthy Again (MAHA) Commission was delayed earlier this month, but leaked documents reveal plans

Measuring how long a cancer treatment extends life (overall survival, or OS) is the best way to judge its effectiveness.

The US Food and Drug Administration (FDA) has given special recognition to a new experimental drug called izalontamab brengitecan (iza-bren).

Eli Lilly is looking for a new leader for its neuroscience division after announcing that Anne White, the current head,